Effect of intracameral human cord blood-derived stem cells on lasered rabbit trabecular meshwork
- 64 Downloads
This study aimed to investigate the effect of intracameral human cord blood stem cells on lasered rabbit trabecular meshwork.
Immediately following diode laser application to the trabecular meshwork, human cord blood stem cells were injected intracamerally, in one eye of 12 albino rabbits. The other eye of ten rabbits was lasered controls and two eyes were normal controls. Rabbits were killed after 4, 8 and 12 weeks.
Lasered control rabbit eyes showed significant disruption of trabecular architecture, loss and pleomorphism of trabecular endothelial cells and progressive narrowing of trabecular spaces till 12 weeks. In contrast, lasered eyes, concurrently injected with human cord blood stem cells, showed relatively preserved endothelial cellularity and structure of the trabecular meshwork, at all time points. Human CD34- and CD44-positive cells were identified in 7/8 eyes treated with stem cells, at 4 and 8 weeks, and 2 of 3 at 12 weeks. Many PKH26-labeled human cord blood cells were visible throughout the trabecular area at 4 weeks. They gradually decreased in number by 8 weeks, and at 12 weeks, they appeared to be oriented along trabecular beams.
There was a relative preservation of cellularity and architecture of the trabecular meshwork in eyes injected with human cord blood stem cells, as compared to lasered control eyes up to 12 weeks, without significant inflammation. This suggests a probable role for such stem cells in eyes with glaucoma, having trabecular dysfunction.
KeywordsIntracameral cord blood cells Trabecular meshwork Stem cells
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving animals
The study was carried out after clearance from our Institutional Animal Ethics and Stem Cell Ethics Committees. The animals were housed in pathogen-free conditions and treated as per the ARVO statement on the use of animals in ophthalmic and vision research. All applicable international, national and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.
Statement on human rights
All procedures performed in studies involving human participants were in accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments.
Informed consent was obtained from all stem cell donors included in the study.
- 6.Spencer WH (1985) Glaucoma. In: Spencer WH (ed) Ocular Pathology, An Atlas and Textbook. WB Saunders, Philadelphia, pp 480–547Google Scholar
- 9.Manuguerra-Gagné R, Boulos PR, Ammar A, Leblond FA, Krosl G, Pichette V, Lesk MR, Roy DC (2013) Transplantation of mesenchymal stem cells promotes tissue regeneration in a glaucoma model through laser-induced paracrine factor secretion and progenitor cell recruitment. Stem Cells 31:1136–1148CrossRefGoogle Scholar
- 15.Keeney M, Chin-Yee I, Weir K, Popma J, Nayar R, Sutherland DR (1998) Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. Int Soc Hematother Graft Eng Cytom 34:61–70Google Scholar
- 24.Jablonska A, Kozlowska H, Markiewicz I, Domanska-Janik K, Lukomska B (2010) Transplantation of neural stem cells derived from human cord blood to the brain of adult and neonatal rats. Acta Neurobiol Exp (Wars) 70:337–350Google Scholar
- 30.Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C, Goldman A, Kersey J, Krivit W, MacMillan ML, Orchard PJ, Peters C, Weisdorf DJ, Ramsay NK, Davies SM (2002) Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100:1611–1618CrossRefGoogle Scholar
- 32.Zhang YJ, Yang YX, Hu MY, Ni QK, Li HG, Miao ZC (2015) Importance of CD44 on umbilical cord mesenchymal stem cells for expansion of hematopoietic cells. Cell Mol Biol (Noisy-le-grand) 61:18–25Google Scholar
- 34.Park SS, Bauer G, Abedi M, Pontow S, Panorgias A, Jonnal R, Zawadzki RJ, Werner JS, Nolta J (2014) Intravitreal autologous bone marrow CD34+ cell therapy for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trial findings. Invest Ophthalmol Vis Sci 56:81–89CrossRefGoogle Scholar
- 36.Subrammaniyan R, Amalorpavanathan J, Shankar R, Rajkumar M, Baskar S, Manjunath SR, Senthilkumar R, Murugan P, Srinivasan VR, Abraham S (2011) Application of autologous bone marrow mononuclear cells in six patients with advanced chronic critical limb ischemia as a result of diabetes: our experience. Cytotherapy 13:993–999CrossRefGoogle Scholar
- 40.Ishikawa F, Shimazu H, Shultz LD, Fukata M, Nakamura R, Lyons B, Shimoda K, Shimoda S, Kanemaru T, Nakamura K, Ito H, Kaji Y, Perry AC, Harada M (2006) Purified human hematopoietic stem cells contribute to the generation of cardiomyocytes through cell fusion. FASEB J 20:950–952CrossRefGoogle Scholar